Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 17, 2021 - Issue 8
Submit an article Journal homepage
3,175
Views
10
CrossRef citations to date
0
Altmetric
Research Paper

Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older

Ulrike K. Buchwalda Merck & Co., Inc., Kenilworth, NJ, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6671-0115View further author information
ORCID Icon,
Charles P. Andrewsb Diagnostics Research Group, San Antonio, TX, USAView further author information
,
John Ervinc Alliance for Multispecialty Research, Knoxville, TN, USAView further author information
,
James T. Petersond Foothill Family Clinic, Salt Lake City, UT, USAView further author information
,
Gretchen M. Tammsa Merck & Co., Inc., Kenilworth, NJ, USAView further author information
,
David Krupae IQVIA, Durham, NC, USAView further author information
,
Patrick Ajiboyee IQVIA, Durham, NC, USAView further author information
,
Lucy Roalfef University College London, London, UKView further author information
,
Andrea L. Kricka Merck & Co., Inc., Kenilworth, NJ, USAView further author information
,
Tina M. Sterlinga Merck & Co., Inc., Kenilworth, NJ, USAView further author information
,
Meihua Wanga Merck & Co., Inc., Kenilworth, NJ, USAView further author information
,
Jason C. Martina Merck & Co., Inc., Kenilworth, NJ, USAView further author information
,
Jon E. Steka Merck & Co., Inc., Kenilworth, NJ, USAORCID Iconhttps://orcid.org/0000-0001-7521-874XView further author information
ORCID Icon,
Melvin A. Kohna Merck & Co., Inc., Kenilworth, NJ, USAView further author information
,
Temitope Folaranmia Merck & Co., Inc., Kenilworth, NJ, USAView further author information
,
Chitrananda Abeygunawardanaa Merck & Co., Inc., Kenilworth, NJ, USAView further author information
,
Jonathan Hartzela Merck & Co., Inc., Kenilworth, NJ, USAView further author information
,
Luwy K. Museya Merck & Co., Inc., Kenilworth, NJ, USAORCID Iconhttps://orcid.org/0000-0001-5484-7037View further author information
ORCID Icon & the V110–029 Study Group show all
Pages 2678-2690 | Received 04 Nov 2020, Accepted 06 Feb 2021, Published online: 21 May 2021

Citations (10)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Laura L. Hammitt, Dean Quinn, Ewa Janczewska, Francisco J. Pasquel, Richard Tytus, K. Rajender Reddy, Katia Abarca, Ilsiyar M. Khaertynova, Ron Dagan, Rachel Dawson, Jennifer McCauley, Tulin Shekar, Wei Fu, Alison Pedley, Tina Sterling, Gretchen Tamms, Luwy Musey & Ulrike K. Buchwald. (2023) Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors. Human Vaccines & Immunotherapeutics 19:1.
Read now

Articles from other publishers (9)

Keshava L. Jetha, Praful D. Bharadia & Manish P. Patel. 2024. Nanocarrier Vaccines. Nanocarrier Vaccines 63 93 .
Philippe De Wals & Michaël Desjardins. (2024) Minimal interval for the administration of a pneumococcal polysaccharide vaccine following the administration of a pneumococcal conjugate vaccine. Vaccine.
Crossref
Miwako Kobayashi, Tamara Pilishvili, Jennifer L. Farrar, Andrew J. Leidner, Ryan Gierke, Namrata Prasad, Pedro Moro, Doug Campos-Outcalt, Rebecca L. Morgan, Sarah S. Long, Katherine A. Poehling & Adam L. Cohen. (2023) Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR. Recommendations and Reports 72:3, pages 1-39.
Crossref
Keiji Okinaka, Yukihiro Akeda, Yoshihiro Inamoto, Shigeo Fuji, Ayumu Ito, Takashi Tanaka, Saiko Kurosawa, Sung-Won Kim, Ryuji Tanosaki, Takuya Yamashita, Chikako Ohwada, Keiji Kurata, Takeshi Mori, Masahiro Onozawa, Kuniko Takano, Hiroki Yokoyama, Katsuyoshi Koh, Koji Nagafuji, Kazutaka Nakayama, Toru Sakura, Tsutomu Takahashi, Kazunori Oishi & Takahiro Fukuda. (2023) Immunogenicity of three versus four doses of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in allogeneic haematopoietic stem cell transplantation recipients: a multicentre, randomized controlled trial. Clinical Microbiology and Infection 29:4, pages 482-489.
Crossref
Momoyo Azuma, Kazunori Oishi, Yukihiro Akeda, Saeko Morino, Yumi Motoki, Masaki Hanibuchi & Yasuhiko Nishioka. (2023) Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged ≥ 65 years: Comparison of booster effects based on intervals of 0.5 and 1.0 year. Vaccine 41:5, pages 1042-1049.
Crossref
Redouane Abouqal, Maher Beji, Mohamed Chakroun, Kamal Marhoum El Filali, Jihane Rammaoui & Hela Zaghden. (2022) Trends in Adult and Elderly Vaccination: Focus on Vaccination Practices in Tunisia and Morocco. Frontiers in Public Health 10.
Crossref
Laura L Hammitt, Dean Quinn, Ewa Janczewska, Francisco J Pasquel, Richard Tytus, K Rajender Reddy, Katia Abarca, Ilsiyar M Khaertynova, Ron Dagan, Jennifer McCauley, Kyeongmi Cheon, Alison Pedley, Tina Sterling, Gretchen Tamms, Luwy Musey & Ulrike K Buchwald. (2022) Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18–49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). Open Forum Infectious Diseases 9:3.
Crossref
Miwako Kobayashi, Jennifer L. Farrar, Ryan Gierke, Amadea Britton, Lana Childs, Andrew J. Leidner, Doug Campos-Outcalt, Rebecca L. Morgan, Sarah S. Long, H. Keipp Talbot, Katherine A. Poehling & Tamara Pilishvili. (2022) Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR. Morbidity and Mortality Weekly Report 71:4, pages 109-117.
Crossref
Joon-Young Song, Chih-Jen Chang, Charles Andrews, Javier Diez-Domingo, Myoung-don Oh, Ron Dagan, Jonathan Hartzel, Alison Pedley, Jianing Li, Tina Sterling, Gretchen Tamms, Joseph A. Chiarappa, Jeannine Lutkiewicz, Luwy Musey, Yingmei Tu & Ulrike K. Buchwald. (2021) Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH). Vaccine 39:43, pages 6422-6436.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.